Related Experiment Videos
Magnesium sulphate versus phenytoin for eclampsia
1Resource Centre for Randomised Trials, Institute of Health Sciences, Old Road, Headington, Oxford, UK, OX3 7LF. lelia.duley@ndm.ox.ac.uk
The Cochrane Database of Systematic Reviews
|October 30, 2003
Summary
Magnesium sulphate significantly reduces recurrent convulsions in women with eclampsia compared to phenytoin. This treatment also lowers risks of pneumonia, ventilation, and intensive care unit admissions for mothers and improves outcomes for newborns.
Area of Science:
- Obstetrics and Gynecology
- Neurology
- Pharmacology
Background:
- Eclampsia is a severe pregnancy complication characterized by seizures, often associated with pre-eclampsia.
- Anticonvulsant medications are crucial for managing eclamptic seizures and preventing recurrence.
Purpose of the Study:
- To compare the efficacy and safety of magnesium sulphate versus phenytoin for treating eclampsia.
- To evaluate the impact of magnesium sulphate on maternal and neonatal outcomes.
Main Methods:
- Systematic review of randomized controlled trials comparing magnesium sulphate with phenytoin for eclampsia treatment.
- Searched Cochrane Pregnancy and Childbirth trials register and Cochrane Central Register of Controlled Trials.
Main Results:
- Magnesium sulphate significantly reduced convulsion recurrence compared to phenytoin (RR 0.31, 95% CI 0.20 to 0.47).
- Magnesium sulphate use was associated with reduced risks of pneumonia, ventilation, and ICU admission.
- Neonatal outcomes improved with magnesium sulphate, showing fewer SCBU admissions and better survival rates.
Conclusions:
- Magnesium sulphate demonstrates superior effectiveness over phenytoin in treating eclampsia.
- The findings support magnesium sulphate as a preferred anticonvulsant for eclamptic patients.